Parkinson's disease in women: Mechanisms underlying sex differences
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Parkinson's disease in women: Mechanisms underlying sex differences
Authors
Keywords
Parkinson's disease, Estrogen replacement therapy, Neuroendocrine, Therapeutic strategies, Molecular, Genetic
Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 895, Issue -, Pages 173862
Publisher
Elsevier BV
Online
2021-01-13
DOI
10.1016/j.ejphar.2021.173862
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant?
- (2020) Marco Bisaglia et al. Biomolecules
- Brain insulin resistance: role in neurodegenerative disease and potential for targeting
- (2020) Christian Hölscher EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Amelioration of diabetes-induced cognitive impairment by Transient Receptor Potential Vanilloid 2 (TRPV2) channel inhibitor: Behavioral and mechanistic study
- (2020) P. Thapak et al. NEUROCHEMISTRY INTERNATIONAL
- Therapeutic potential of pharmacological agents targeting TRP channels in CNS disorders
- (2020) Pavan Thapak et al. PHARMACOLOGICAL RESEARCH
- Transient Receptor Potential Channels as an Emerging Target for the Treatment of Parkinson’s Disease: An Insight Into Role of Pharmacological Interventions
- (2020) Bhupesh Vaidya et al. Frontiers in Cell and Developmental Biology
- Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease
- (2019) Dilan Athauda et al. JAMA Neurology
- A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
- (2019) Wonsuk Shin et al. Drug Design Development and Therapy
- Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2019) Valery L Feigin et al. LANCET NEUROLOGY
- CARDIOVASCULAR BENEFIT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RECENT CARDIOVASCULAR OUTCOME TRIALS
- (2019) David Aguilar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Probing the Origin of the Toxicity of Oligomeric Aggregates of α-Synuclein with Antibodies
- (2019) Roberta Cascella et al. ACS Chemical Biology
- Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study
- (2019) Mutsumi Iijima et al. EXPERT OPINION ON PHARMACOTHERAPY
- Antibodies against alpha‐synuclein: tools and therapies
- (2019) Nishant N. Vaikath et al. JOURNAL OF NEUROCHEMISTRY
- Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054
- (2019) Miroslaw Brys et al. MOVEMENT DISORDERS
- Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease
- (2019) Yang Hyun Lee et al. Scientific Reports
- Decreased risk of Parkinson’s disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis
- (2019) Yueli Zhu et al. PLoS One
- Luteolin-7-O-glucoside protects dopaminergic neurons by activating estrogen-receptor-mediated signaling pathway in MPTP-induced mice
- (2019) Liyue Qin et al. TOXICOLOGY
- Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson’s Disease
- (2018) T. N. Seyfried et al. ASN Neuro
- MitoQ protects dopaminergic neurons in a 6-OHDA induced PD model by enhancing Mfn2-dependent mitochondrial fusion via activation of PGC-1α
- (2018) Ye Xi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease
- (2018) Rizwan S. Akhtar et al. JOURNAL OF NEUROCHEMISTRY
- Participation of Women in Clinical Trials
- (2018) Louise Pilote et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
- (2018) Liping Zhang et al. NEUROPEPTIDES
- An update on new and unique uses of botulinum toxin in movement disorders
- (2018) Joseph Jankovic TOXICON
- Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?
- (2018) Margherita Torti et al. EXPERT OPINION ON PHARMACOTHERAPY
- Postnatal developmental trajectory of dopamine receptor 1 and 2 expression in cortical and striatal brain regions
- (2018) Ellen R. Cullity et al. JOURNAL OF COMPARATIVE NEUROLOGY
- Emerging Treatment Approaches for Parkinson’s Disease
- (2018) Thomas B. Stoker et al. Frontiers in Neuroscience
- PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
- (2018) Fabiana Núñez et al. Frontiers in Pharmacology
- A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism
- (2018) Adam Book et al. Frontiers in Neurology
- Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation
- (2018) Sineadh M. Conway et al. NEUROPHARMACOLOGY
- The role of monogenic genes in idiopathic Parkinson’s disease
- (2018) Xylena Reed et al. NEUROBIOLOGY OF DISEASE
- Prooxidant–antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease
- (2017) Jadranka Miletić et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- The relevance of gender in Parkinson’s disease: a review
- (2017) Marina Picillo et al. JOURNAL OF NEUROLOGY
- One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan
- (2017) Hirotaka Iwaki et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Botulinum Toxin in Parkinson Disease Tremor
- (2017) Shivam Om Mittal et al. MAYO CLINIC PROCEEDINGS
- Sex disparities in access to caregiving in Parkinson disease
- (2017) Nabila Dahodwala et al. NEUROLOGY
- Caffeine as symptomatic treatment for Parkinson disease (Café-PD)
- (2017) Ronald B. Postuma et al. NEUROLOGY
- A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease
- (2017) Jaishree Jalewa et al. NEUROPHARMACOLOGY
- Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles
- (2017) Marika Doucet et al. PLoS One
- Botulinum Toxin Therapy for Parkinson's Disease
- (2017) Irene Malaty et al. SEMINARS IN NEUROLOGY
- Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections
- (2017) Olivia Samotus et al. PLoS One
- Cognitive Impairment Associated with Parkinson's Disease: Role of Mitochondria
- (2016) Nihar R. Das et al. Current Neuropharmacology
- Neuroendocrine abnormalities in Parkinson's disease
- (2016) Eduardo De Pablo-Fernández et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development
- (2016) Richa Hanamsagar et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Neuroprotective role of (Val8) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease
- (2016) Yue-ze Liu et al. Neural Regeneration Research
- Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs
- (2016) Jong-Woo Jeong et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson’s disease: Involvement of antioxidative enzymes induction
- (2015) Chi-Rei Wu et al. CHEMICO-BIOLOGICAL INTERACTIONS
- GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
- (2015) Eva W. Iepsen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis
- (2015) Frédéric Moisan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- The therapeutic potential of cannabinoids for movement disorders
- (2015) Benzi Kluger et al. MOVEMENT DISORDERS
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2015) W. Liu et al. NEUROSCIENCE
- Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson’s Disease
- (2015) Md Shahaduzzaman et al. PLoS One
- Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson’s disease model
- (2014) Masanori Itakura et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Thyroid Status and Cognitive Function in Euthyroid Patients with Early Parkinson's Disease
- (2014) Seong-Min Choi et al. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- Effects of the root bark of Paeonia suffruticosa on mitochondria-mediated neuroprotection in an MPTP-induced model of Parkinson’s disease
- (2014) Hyo Geun Kim et al. FOOD AND CHEMICAL TOXICOLOGY
- AC-186, a Selective Nonsteroidal Estrogen Receptor β Agonist, Shows Gender Specific Neuroprotection in a Parkinson’s Disease Rat Model
- (2013) Krista McFarland et al. ACS Chemical Neuroscience
- Istradefylline: First Global Approval
- (2013) Rosselle Dungo et al. DRUGS
- Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration
- (2013) Jee-Won Sul et al. HUMAN MOLECULAR GENETICS
- Gender differences in Parkinson’s disease: focus on plasma alpha-synuclein
- (2013) Giovanni Caranci et al. JOURNAL OF NEURAL TRANSMISSION
- Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation
- (2013) Therese Fagerqvist et al. JOURNAL OF NEUROCHEMISTRY
- Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease
- (2013) Veronica Antipova et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Widespread sex differences in gene expression and splicing in the adult human brain
- (2013) Daniah Trabzuni et al. Nature Communications
- GDNF Contributes to Oestrogen-Mediated Protection of Midbrain Dopaminergic Neurones
- (2012) F. L. Campos et al. JOURNAL OF NEUROENDOCRINOLOGY
- Antibody-Aided Clearance of Extracellular -Synuclein Prevents Cell-to-Cell Aggregate Transmission
- (2012) E.-J. Bae et al. JOURNAL OF NEUROSCIENCE
- Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease
- (2012) Paolo Solla et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1
- (2012) Jordan J. Elm et al. MOVEMENT DISORDERS
- Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease
- (2012) C. Laloux et al. PHARMACOLOGICAL RESEARCH
- α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls
- (2012) Lynnae M. Smith et al. PLoS One
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- Gender segregation in gene expression and vulnerability to oxidative stress induced injury in ventral mesencephalic cultures of dopamine neurons
- (2011) Qingqing Tao et al. JOURNAL OF NEUROSCIENCE RESEARCH
- The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease
- (2011) Azza M. Baraka et al. LIFE SCIENCES
- Effect of Different Doses of Estrogen on the Nigrostriatal Dopaminergic System in Two 6-Hydroxydopamine-Induced Lesion Models of Parkinson’s Disease
- (2011) Marcela Ferreira Cordellini et al. NEUROCHEMICAL RESEARCH
- Estrogen protects against amyloid-β toxicity by estrogen receptor α-mediated inhibition of Daxx translocation
- (2011) Laura Mateos et al. NEUROSCIENCE LETTERS
- Vaccination for Parkinson's disease
- (2011) A. Schneeberger et al. PARKINSONISM & RELATED DISORDERS
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
- (2011) Eliezer Masliah et al. PLoS One
- The Role of Environmental Exposures in Neurodegeneration and Neurodegenerative Diseases
- (2011) Jason R. Cannon et al. TOXICOLOGICAL SCIENCES
- Gender differences in Parkinson's disease: Clinical characteristics and cognition
- (2010) Ivy N. Miller et al. MOVEMENT DISORDERS
- Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease
- (2010) Andreas Wree et al. NEUROBIOLOGY OF DISEASE
- Detection of elevated levels of soluble -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies
- (2009) K. E. Paleologou et al. BRAIN
- Anti-aggregation and fibril-destabilizing effects of sex hormones on α-synuclein fibrils in vitro
- (2009) Mie Hirohata et al. EXPERIMENTAL NEUROLOGY
- Neuroprotective actions of sex steroids in Parkinson’s disease
- (2009) Mélanie Bourque et al. FRONTIERS IN NEUROENDOCRINOLOGY
- Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens
- (2009) Glenda E. Gillies et al. HORMONES AND BEHAVIOR
- Osteoporosis in Parkinson's disease
- (2009) Marco Invernizzi et al. PARKINSONISM & RELATED DISORDERS
- The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats
- (2009) Karen L. Eskow et al. SYNAPSE
- Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease
- (2008) Pramod Kumar et al. BEHAVIOURAL BRAIN RESEARCH
- Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
- (2008) A. Munoz et al. BRAIN
- Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
- (2008) Jiang-Fan Chen et al. CURRENT PHARMACEUTICAL DESIGN
- Fas-associated factor 1 and Parkinson's disease
- (2008) Ranjita Betarbet et al. NEUROBIOLOGY OF DISEASE
- Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET
- (2007) Hristina Jovanovic et al. NEUROIMAGE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started